Synthesis and preliminary evaluation of 99mTc-Hynic-fragments [F(ab')2 and F(ab')] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin's lymphoma.
Appl Radiat Isot
; 153: 108808, 2019 Nov.
Article
in En
| MEDLINE
| ID: mdl-31325798
ABSTRACT
This study was to evaluate the potential of 99mTc-Hynic-fragments of Rituximab as radioimmunoscintigraphic agents for diagnosis of patients with Non-Hodgkin's Lymphoma (NHL). Rituximab was digested with immobilized pepsin and papain to yield F(ab')2-Rituximab and F(ab')-Rituximab fragments respectively. Purified fragments were characterized by SE-HPLC and SDS-PAGE and subsequently radiolabeled with technetium-99m using Hynic as bifunctional chelator. The 99mTc-Hynic-F(ab')2-Rituximab and 99mTc-Hynic-F(ab')-Rituximab exhibited good in-vitro stability and specificity to Raji cells. Biodistribution studies demonstrated rapid pharmacokinetics and clearance predominantly through renal route.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Technetium
/
Radioimmunodetection
/
Rituximab
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Appl Radiat Isot
Journal subject:
MEDICINA NUCLEAR
/
SAUDE AMBIENTAL
Year:
2019
Document type:
Article
Affiliation country: